Current Report Filing (8-k)
February 06 2020 - 5:29PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 31, 2020
Bellicum Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36783
|
|
20-1450200
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
2130 W. Holcombe Blvd., Ste. 800
Houston, TX
|
|
77030
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: 832-384-1100
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, par value
$0.01 per share
|
|
BLCM
|
|
The Nasdaq Global Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.02
|
Termination of a Material Definitive Agreement.
|
On January 31, 2020 Bellicum Pharmaceuticals, Inc. (the Company) notified Cancer Prevention and Research Institute of Texas of the Companys
election to terminate the Cancer Research Grant Contract, dated August 9, 2017, effective 30 days from the date of notice.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Bellicum Pharmaceuticals, Inc.
|
|
|
|
|
Dated: February 6, 2020
|
|
|
|
By:
|
|
/s/ Richard A. Fair
|
|
|
|
|
|
|
Richard A. Fair
|
|
|
|
|
|
|
President and Chief Executive Officer
|
Bellicum Pharmaceuticals (PK) (USOTC:BLCM)
Historical Stock Chart
From Jul 2024 to Aug 2024
Bellicum Pharmaceuticals (PK) (USOTC:BLCM)
Historical Stock Chart
From Aug 2023 to Aug 2024